Xiamen Innovax and Sanofi Pasteur enter into license agreement related to rotavirus vaccines
July 28, 2020, Xiamen Innovax Biotech Co Ltd (“Innovax”) announced that a license agreement is signed to grant certain rights to Sanofi related to rotavirus vaccines.
The licensed rotavirus technology, originally developed under a collaboration between Innovax and Xiamen University, can induce high titer and broadly reactive protective antibodies against various serotypes of rotavirus in animals. The agreement grants Sanofi global rights to develop, manaufacture and commercialize this rotavirus technology. Per the Agreement, Xiamen Innovax has the right to obtain from Sanofi a sub-license of the granted rights above for the development of a rotavirus vaccine for China. The agreement contains an upfront, development milestones and royalties. Further financial details are undisclosed.
Xiamen University (XMU) was established in 1921 and is well-known in biomedical field. XMU owned two well-established institutions– National Institute of Diagnostic and Vaccine Development in Infectious Diseases (NIDVD) and Key Laboratory of Molecular Vaccinology and Molecular Diagnostics (SKLVD). XMU and Xiamen Innovax co-developed the only licensed hepatitis E vaccine in the world and the first licensed domestic human papillomavirus vaccine in China.
About Innovax
Xiamen Innovax Biotech CO., LTD. (Innovax) is a wholly owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD under YangShengTang Group. Established in 2005, INNOVAX, has been dedicating to provide Innovative、Reliable and Affordable vaccine for people in need to combat infectious disease.
Innovax is a high-tech enterprise in China, has established a core-platform using recombinant technology to express protein in E. coli for vaccine development and commercialization.
Based on this platform, the world’s first Hepatitis E Vaccine, Hecolin® was launched in China in October 2012. Its Cervical Cancer Vaccine--Cecolin® (HPV16&18 bivalent,) have been approved in December 2019. Furthermore, a 9-valent HPV vaccine is about to start its phase III clinical trial.
To learn more about Innovax, please visit www.innovax.cn/en/index.aspx.
The licensed rotavirus technology, originally developed under a collaboration between Innovax and Xiamen University, can induce high titer and broadly reactive protective antibodies against various serotypes of rotavirus in animals. The agreement grants Sanofi global rights to develop, manaufacture and commercialize this rotavirus technology. Per the Agreement, Xiamen Innovax has the right to obtain from Sanofi a sub-license of the granted rights above for the development of a rotavirus vaccine for China. The agreement contains an upfront, development milestones and royalties. Further financial details are undisclosed.
This license agreement with Sanofi is another global vaccine transaction with a global leading vaccine company that has resulted from the successful collaboration between Innovax and Xiamen University.
Xiamen University (XMU) was established in 1921 and is well-known in biomedical field. XMU owned two well-established institutions– National Institute of Diagnostic and Vaccine Development in Infectious Diseases (NIDVD) and Key Laboratory of Molecular Vaccinology and Molecular Diagnostics (SKLVD). XMU and Xiamen Innovax co-developed the only licensed hepatitis E vaccine in the world and the first licensed domestic human papillomavirus vaccine in China.
About Innovax
Xiamen Innovax Biotech CO., LTD. (Innovax) is a wholly owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD under YangShengTang Group. Established in 2005, INNOVAX, has been dedicating to provide Innovative、Reliable and Affordable vaccine for people in need to combat infectious disease.
Innovax is a high-tech enterprise in China, has established a core-platform using recombinant technology to express protein in E. coli for vaccine development and commercialization.
Based on this platform, the world’s first Hepatitis E Vaccine, Hecolin® was launched in China in October 2012. Its Cervical Cancer Vaccine--Cecolin® (HPV16&18 bivalent,) have been approved in December 2019. Furthermore, a 9-valent HPV vaccine is about to start its phase III clinical trial.
To learn more about Innovax, please visit www.innovax.cn/en/index.aspx.
